🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients

RecruitingPhase 2Ages 18 Years - anyFemaleNational Cancer Center, Korea
NCT06780748 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Sentinel lymph node biopsy (SLNB) is essential for staging and treatment planning in early breast cancer patients. As a less invasive procedure, it has replaced axillary lymph node dissection (ALND) by reducing complications and improving patient outcomes. However, the 10-year local recurrence rate for breast cancer is approximately 2-10%, and the role of SLNB in the surgical management of recurrent breast cancer remains unclear. According to the NCCN guidelines and Korean Breast Cancer Treatment Recommendations, surgical management for recurrent breast cancer includes mastectomy and axillary lymph node surgery for patients who have previously undergone breast-conserving surgery and radiotherapy. For axillary recurrence, surgery is recommended if feasible, followed by radiotherapy. Conversely, the ASCO guidelines recommend SLNB for surgically resectable recurrent breast cancer, and rece

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with ipsilateral locally recurrent breast cancer who previously underwent ipsilateral axillary surgery. * Female patients aged 18 years or older. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Patients who voluntarily decide to participate in the study and provide written informed consent. Exclusion Criteria: * Patients with distant metastases. * Patients who previously underwent ipsilateral mastectomy. * Pregnant or breastfeeding women. * Patients with a general condition that impairs the ability to understand or provide informed consent.
💊

What it tests

  • Identification rate of sentinel lymph node
📍

Where

1 site
National Cancer Center
Goyang-si, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy